Discover and read the best of Twitter Threads about #JubilantPharmova
Most recents (2)
#JubilantPharmova Q3 FY22 concall highlights 💊💊
Like & retweet for better reach !
1. The company’s performance for the quarter was affected by headwinds in the pharmaceutical business.
Like & retweet for better reach !
1. The company’s performance for the quarter was affected by headwinds in the pharmaceutical business.
But was partly mitigated due to robust performance in the Contract Research and Development Services (CRDS) segment.
2. While the Radiopharma business showed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market.
Nice Call Based on #HarmonicPatterns by Rohan Bhai ...
Even #Fundamentals are Good & Other #Technicals are giving additional confirmation ...
See Detailed Analysis in 🧵Below
Even #Fundamentals are Good & Other #Technicals are giving additional confirmation ...
See Detailed Analysis in 🧵Below
1⃣
Jubilant Pharmova Ltd, formerly Jubilant Life Sciences Ltd, is an India-based pharmaceuticals company.
The Company’s segments include Pharmaceuticals, Contract Research and Development Services, and Proprietary Novel Drugs.
#JUBLPHARMA
Jubilant Pharmova Ltd, formerly Jubilant Life Sciences Ltd, is an India-based pharmaceuticals company.
The Company’s segments include Pharmaceuticals, Contract Research and Development Services, and Proprietary Novel Drugs.
#JUBLPHARMA
2⃣
🌟Few Fundamental Positives 🌟
✅Company Market Cap – 12,418.35 Cr
✅Promoter Holding Pledge – 0%
✅Financial Ratios like P/E Ratio from TTM data are of no use as Life Science Ingredients (LSI) business demerged from it with effect from February 1, 2021.
#JUBLPHARMA
🌟Few Fundamental Positives 🌟
✅Company Market Cap – 12,418.35 Cr
✅Promoter Holding Pledge – 0%
✅Financial Ratios like P/E Ratio from TTM data are of no use as Life Science Ingredients (LSI) business demerged from it with effect from February 1, 2021.
#JUBLPHARMA
